Artelo Biosciences Inc ARTL Finanças

Artelo Biosciences Inc. (ARTL) Fundamentals


Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Artelo Biosciences Inc is a United States based development-stage biopharmaceutical company. It is focused on discovering, licensing, developing and commercializing treatments that control the endocannabinoid system. The company seeks to pursue technologies and programs that offer proprietary approaches to cannabinoid-based therapies, including those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds that promote the effectiveness of the endocannabinoid system. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

SHARE INFORMATION
Market Cap	US$ 10.563.305
Shares Outstanding	2.839.598
Float	2.815.275
Percent Float	99,14%
Short Interest	0,00
Short Percent Float	0,0%
Short Interest Ratio	0,00
Short Interest Date	-
Latest Fiscal Dividend Per Share	US$ 0,00
Latest Fiscal Revenue	US$ 0
Latest Fiscal EPS	US$ -6,00
Latest Fiscal Date	2021-08-31

DIVIDENDS
Dividend (3 Years)	US$ 0,00
Dividend (5 Years)	US$ 0,00
Ex Dividend Date	-
Dividend Rate	US$ 0,00
Dividend Yield	0,0%
Payment Cash	-

HOLDERS
Institutions	33
Institutional Holdings Date	2022-07-31
Institutional Bought Previous 3 Months	112.304
Institutional Holdings Percent	7,4%
Institutional Sold Previous 3 Months	598.566
Insider Holdings Date	2022-07-31
Insider Bought Previous 3 Months	60.000
Insider Holdings Percent	2,2
Insider Sold Previous 3 Months	-
Insider Shares Owned	938.037

TRADING INFO
52 Week High	US$ 19,80
52 Week Low	US$ 3,61
52 Week High Change	US$ -72,89
21 Day Moving Average	US$ 5,091
21 Day Extended Moving Average	US$ 4,8548
50 Day Moving Average	US$ 5,039
50 Day Extended Moving Average	US$ 5,0527
200 Day Moving Average	US$ 6,9586
200 Day Extended Moving Average	US$ 7,2492
10 Day Average Volume	105.101
20 Day Average Volume	58.524
30 Day Average Volume	46.160
50 Day Average Volume	37.401
Alpha	-0.040092
Beta	1.2510
Standard Deviation	0.230624
R2	0.078603
7 Day Price Change	US$ -1,98
7 Day Percent Change	-34,74%
21 Day Price Change	US$ -1,76
21 Day Percent Change	-32,07%
30 Day Price Change	US$ -1,51
30 Day Percent Change	-28,86%
Month to Date Price Change	US$ -1,38
Month to Date Percent Change	-27,08%
Quarter to Date Price Change	US$ -1,03
Quarter to Date Percent Change	-21,72%
180 Day Price Change	US$ -2,15
180 Day Percent Change	-36,64%
200 Day Price Change	US$ -2,20
200 Day Percent Change	-37,12%
Year to Date Price Change	US$ -4,07
Year to Date Percent Change	-52,22%

Artelo Biosciences Inc. (ARTL) Key Ratios

PROFITABILITY
EBIT Margin	0,0%
EBITDA Margin	0,0%
Pre-Tax Profit Margin	0,0%
Profit Margin Count	0,0%
Gross Margin	0,0%
Profit Margin TOT	0,0%

INCOME STATEMENTS
Revenue	US$ 0
Revenue Per Share	US$ 0,00
Revenue (3 Years)	US$ 0,00
Revenue (5 Years)	US$ 0,00

FINANCIAL STRENGTH
Price to Tangible Book	0,50
Total Debt To Equity	0,00
Int Coverage	0,00
Current Ratio	28,10
Leverage Ratio	1,00
Quick Ratio	26,90
Long Term Debt To Capital	0,00

VALUATION MEASURES
PE Ratio	-0,80
Enterprise Value	US$ -12.071.325
Price to Sales	0,00
Price to Free Cash	-1,80
PE High Last 5 Years	0,00
Price To Book	0,40
Price To Cash Flow	0,00
PE Low Last 5 Years	0,00
Price to Tangible Book	0,50

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0,00
Invoice Turnover	0,00
Assets Turnover	0,00
Return Assets	-50,49
Return on Equity	-52,47
Return on Capital	-34,52

Artelo Biosciences Inc. (ARTL) Profile

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	MaloneBailey, LLP
CEO	Gregory D. Gorgas
Emplyoees	2
Last Audit	UQ
CIK	0001621221
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	888 Prospect Street Suite 210 San Diego, CA 92037
Website	http://www.artelobio.com
Facsimile	-
Telephone	+1 760 943-1689
Email	-

Seu Histórico Recente

NASDAQ

ARTL

Artelo Bio..

Registre-se agora para acompanhar essas ações ao vivo no Monitor ADVFN.

O Monitor permite ver até 110 de suas ações favoritas de uma vez só e é completamente grátis para você usar.

Faça o login em ADVFN

Registrar agora

Cotações da NYSE e AMEX têm defasagem de no mínimo 20 minutos.
Quaisquer outras cotações têm defasagem de no mínimo 15 minutos quando não especificado.
Em caso de dúvidas por favor entre em contato com o suporte: suporte@advfn.com.br ou (11) 4950 5808.

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V:br D:20220813 20:50:06